Prostate Cancer Biomarker Analysis-optrascan

By Author: OptraSCAN
Total Articles: 15
Comment this article

OptraSCAN offers Prostate Cancer Biomarker Analysis the leading end-to-end digital pathology solution, provider.

The classical Gleason grading system is exclusively based on visual assessment of architectural patterns of prostate adenocarcinoma acknowledged by WHO and further modified and revised in 2004 and 2016 by the International Society of Urological Pathology (ISUP), is a powerful prognostic predictor for patients with prostate carcinoma. However, the histological assessment by pathologists of these tissue slides to evaluate the morphological patterns is often time-consuming and suffers from limited reproducibility. Studies published have reported Intra and Interobserver agreement variability. With the FDA approval for whole slide imaging systems and with rapid technological advances and the advent of computer-aided platforms, the development of machine-based scoring algorithms shows promise in overcoming these challenges and provides a possible approach to accurate, rapid, and reproducible analysis.

Prostate cancer is ...
... the most prevalent form of cancer and the second most common cause of death among men in the United States. Automated and deep learning approaches by comparing morphological and quantitative information on digital pathology images have the potential to overcome the above-mentioned limitations to quantitatively characterize the Gleason spectrum and generate reproducible results”, said Anand Maiskar, VP – Sales ROW, OptraScan.

Tel: +1-408-524-5300
Contact us at- info@optrascan.com